Pfizer Inc. (PFE)

28.34 -0.27 (-0.94%) At close: 04:00PM EDT

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323
https://www.pfizer.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 88,000

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Albert Bourla D.V.M., Ph.D.	Chairman of the Board & CEO	4.05M	N/A	1962
Mr. David M. Denton	Chief Financial Officer & Executive VP	1.75M	N/A	1965
Dr. Mikael Dolsten M.D., Ph.D.	Chief Scientific Officer and President of Research & Development	2.41M	N/A	1958
Mr. Douglas M. Lankler	Executive VP & General Counsel	1.76M	N/A	1966
Ms. Jennifer B. Damico	Senior VP, Controller & Principal Accounting Officer	N/A	N/A	1968
Ms. Lidia L. Fonseca	Executive VP and Chief Digital & Technology Officer	N/A	N/A	1969
Ms. Francesca M. DeMartino	Chief Investor Relations Officer	N/A	N/A	N/A
Mr. Rady A. Johnson	Executive VP and Chief Compliance, Quality & Risk Officer	N/A	N/A	1962
Mr. Andreas J. Panayiotou	Global Chief Marketing Officer	N/A	N/A	N/A
Ms. Payal Sahni Becher	Chief People Experience Officer & Executive VP	N/A	N/A	1975

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Corporate governance

Pfizer Inc.’s ISS governance QualityScore as of 1 October 2024 is 7. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.